Ligand Pharms Glucagon
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Ligand Pharms Glucagon - Asset Resilience Ratio
Ligand Pharms Glucagon (LGNXZ) has an Asset Resilience Ratio of 18.70% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Ligand Pharms Glucagon's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Ligand Pharms Glucagon's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $177.35 Million | 18.7% |
| Total Liquid Assets | $177.35 Million | 18.70% |
Asset Resilience Insights
- Good Liquidity Position: Ligand Pharms Glucagon maintains a healthy 18.70% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Ligand Pharms Glucagon Industry Peers by Asset Resilience Ratio
Compare Ligand Pharms Glucagon's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for Ligand Pharms Glucagon (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Ligand Pharms Glucagon.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 19.52% | $183.86 Million | $941.77 Million | +0.80pp |
| 2023-12-31 | 18.72% | $147.35 Million | $787.22 Million | -3.16pp |
| 2022-12-31 | 21.88% | $166.86 Million | $762.67 Million | -2.90pp |
| 2021-12-31 | 24.78% | $321.59 Million | $1.30 Billion | -1.90pp |
| 2020-12-31 | 26.69% | $363.57 Million | $1.36 Billion | -40.09pp |
| 2019-12-31 | 66.78% | $998.32 Million | $1.49 Billion | +17.47pp |
| 2018-12-31 | 49.32% | $647.41 Million | $1.31 Billion | +24.26pp |
| 2017-12-31 | 25.05% | $181.04 Million | $722.65 Million | +4.72pp |
| 2016-12-31 | 20.33% | $122.30 Million | $601.59 Million | -0.10pp |
| 2015-12-31 | 20.43% | $102.79 Million | $503.06 Million | +17.67pp |
| 2014-12-31 | 2.76% | $7.13 Million | $258.03 Million | -1.38pp |
| 2013-12-31 | 4.14% | $4.34 Million | $104.71 Million | +1.49pp |
| 2012-12-31 | 2.65% | $2.77 Million | $104.26 Million | -5.52pp |
| 2011-12-31 | 8.17% | $10.00 Million | $122.35 Million | -17.44pp |
| 2010-12-31 | 25.61% | $19.35 Million | $75.56 Million | -0.62pp |
| 2009-12-31 | 26.23% | $37.20 Million | $141.81 Million | -4.05pp |
| 2008-12-31 | 30.28% | $51.92 Million | $171.45 Million | +20.13pp |
| 2007-12-31 | 10.15% | $17.60 Million | $173.28 Million | +6.03pp |
| 2006-12-31 | 4.12% | $13.45 Million | $326.05 Million | -8.85pp |
| 2005-12-31 | 12.98% | $20.17 Million | $155.45 Million | -- |